Full Press Release Details
lynozyfic linvoseltamab gcpt receives fda accelerated approval for treatment of relapsed or refractory multiple myeloma.
REGN
lynozyfic linvoseltamab gcpt receives fda accelerated approval for treatment of relapsed or refractory multiple myeloma
Key Takeaway: lynozyfic linvoseltamab gcpt receives fda accelerated approval for treatment of relapsed or refractory multiple myeloma